SG10202110138TA - Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine - Google Patents

Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Info

Publication number
SG10202110138TA
SG10202110138TA SG10202110138TA SG10202110138TA SG 10202110138T A SG10202110138T A SG 10202110138TA SG 10202110138T A SG10202110138T A SG 10202110138TA SG 10202110138T A SG10202110138T A SG 10202110138TA
Authority
SG
Singapore
Prior art keywords
polyalkyleneimine
particles
complex
double
pharmaceutical composition
Prior art date
Application number
Inventor
Rubio Mercedes Pozuelo
Ortiz Marisol Quintero
García Ana Villanueva
Original Assignee
Highlight Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54557307&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202110138T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Highlight Therapeutics S L filed Critical Highlight Therapeutics S L
Publication of SG10202110138TA publication Critical patent/SG10202110138TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202110138T 2015-11-17 2016-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine SG10202110138TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194864 2015-11-17

Publications (1)

Publication Number Publication Date
SG10202110138TA true SG10202110138TA (en) 2021-10-28

Family

ID=54557307

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202110138T SG10202110138TA (en) 2015-11-17 2016-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
SG11201803949RA SG11201803949RA (en) 2015-11-17 2016-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201803949RA SG11201803949RA (en) 2015-11-17 2016-11-17 Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine

Country Status (20)

Country Link
US (2) US10568971B2 (en)
EP (3) EP4183386A1 (en)
JP (2) JP6710415B6 (en)
KR (1) KR102317281B1 (en)
CN (3) CN112294758B (en)
AU (2) AU2016355972B2 (en)
CA (1) CA3005492C (en)
CH (1) CH713097B1 (en)
DE (2) DE112016003047B4 (en)
DK (1) DK3319587T3 (en)
EA (1) EA037117B1 (en)
ES (2) ES2715251B1 (en)
GB (1) GB2555364A (en)
HU (1) HUE047172T2 (en)
IL (2) IL257393B (en)
MX (1) MX2018005971A (en)
PL (1) PL3319587T3 (en)
PT (1) PT3319587T (en)
SG (2) SG10202110138TA (en)
WO (1) WO2017085228A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102589295B1 (en) 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 Improved polyethyleneimine polyethyleneglycol vectors
DK3326641T3 (en) 2015-04-22 2019-09-30 Curevac Ag RNA-Containing Composition for the Treatment of Tumor Diseases
CN114835923A (en) * 2015-08-13 2022-08-02 约翰霍普金斯大学 Method for preparing polyelectrolyte complex nanoparticles
JP2020520368A (en) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ Novel pharmaceutical composition containing particles containing complex of double-stranded polyribonucleotide and polyalkyleneimine
CN107550885B (en) * 2017-07-31 2021-08-13 华中科技大学同济医学院附属协和医院 Nanoparticle carrier containing TLR3 ligand in pattern recognition receptor and preparation method and application thereof
CN107693789B (en) * 2017-07-31 2021-08-13 华中科技大学同济医学院附属协和医院 Compound containing cell-targeted antibody and Poly (I: C) and preparation method and application thereof
JP2022507840A (en) * 2018-11-21 2022-01-18 ハイライト セラピューティクス エセ．エレ． Nanoplexed poly (I: C) preparation and its use
JP7459449B2 (en) * 2019-04-26 2024-04-02 東レ株式会社 Adsorption material for soluble tumor necrosis factor receptors
US20220313724A1 (en) * 2021-05-17 2022-10-06 Highlight Therapeutics, S.L. Compositions for intratumoral administration and related methods
US20240091348A1 (en) 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1820588A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
ATE535231T1 (en) 2002-07-03 2011-12-15 Oncovir Inc METHOD FOR PRODUCING POLY-ICLC AND USE THEREOF
JP2006506433A (en) 2002-11-18 2006-02-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム Targeted double-stranded RNA-mediated cell killing
EP1886688A4 (en) * 2005-05-30 2013-01-09 Nippon Shinyaku Co Ltd Method for producing nucleic acid-containing complex preparation
CN103405762A (en) * 2005-06-08 2013-11-27 依生生物制药(新加坡)私人有限公司 Polyinosinic acid-polycytidylic acid dominated adjuvant
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
JP4861036B2 (en) 2006-03-31 2012-01-25 リンテック株式会社 Release sheet and method for producing the same
WO2008057696A2 (en) 2006-10-10 2008-05-15 Juvaris Biotherapeutics, Inc. Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof
EP2047858A1 (en) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
KR100958293B1 (en) 2008-03-27 2010-05-19 단국대학교 산학협력단 Allosteric trans?splicing group I ribozyme whose activity of target-specific RNA replacement is controlled by theophylline
EP3705493A1 (en) * 2008-12-22 2020-09-09 TargImmune Therapeutics AG Egfr-homing double-stranded rna vector for systemic cancer treatment
ES2368963B1 (en) * 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii PROCEDURE FOR IDENTIFICATION OF THERAPEUTIC AGENTS AGAINST MELANOMA AND USE OF IDENTIFIED AGENT.
CN102471306B (en) 2009-07-07 2013-10-30 先正达参股股份有限公司 Microbiocides
CN102988303A (en) 2011-09-15 2013-03-27 天津泽世德生物医药有限公司 Preparation method of polyinosinic acid-polycytidylic acid lyophilized powder injection
US20140234373A1 (en) * 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
US9226936B2 (en) 2011-10-28 2016-01-05 The Wistar of Anatomy and Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
WO2013087083A1 (en) * 2011-12-15 2013-06-20 Biontech Ag Particles comprising single stranded rna and double stranded rna for immunomodulation
KR102240042B1 (en) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
ITRM20120480A1 (en) 2012-10-09 2014-04-10 Uni Degli Studi Camerino MULTICOMPONENT LIPID NANOPARTICLES AND PROCEDURES FOR THEIR PREPARATION.
US20140335154A1 (en) 2013-03-12 2014-11-13 Multicell Immunotherapeutics, Inc. Methods and formulations to achieve tumor targeted double stranded rna mediated cell death
MX2016005883A (en) 2013-11-06 2016-08-17 Janssen Sciences Ireland Uc Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections.
CN103599071B (en) 2013-11-08 2016-01-27 杭州美亚药业股份有限公司 A kind of preparation method of polyinosinic-polycytacidic acidic dry powder
KR102589295B1 (en) * 2014-05-14 2023-10-13 타르그이뮨 테라퓨틱스 아게 Improved polyethyleneimine polyethyleneglycol vectors

Also Published As

Publication number Publication date
SG11201803949RA (en) 2018-06-28
JP6896914B2 (en) 2021-06-30
AU2020201605B2 (en) 2022-05-26
CN112294757B (en) 2024-02-13
IL257393B (en) 2020-02-27
KR20180074781A (en) 2018-07-03
EP3639811C0 (en) 2024-03-20
GB2555364A (en) 2018-04-25
AU2020201605A1 (en) 2020-03-19
JP2020143088A (en) 2020-09-10
PT3319587T (en) 2019-11-20
IL272238A (en) 2020-02-27
EP3639811A1 (en) 2020-04-22
EA037117B1 (en) 2021-02-09
MX2018005971A (en) 2019-01-31
ES2715251A2 (en) 2019-06-03
CN107920993B (en) 2020-11-20
ES2715251R1 (en) 2019-11-28
ES2715251B1 (en) 2020-09-07
AU2016355972B2 (en) 2019-12-05
EP4183386A1 (en) 2023-05-24
JP2018537398A (en) 2018-12-20
JP6710415B6 (en) 2020-07-29
ES2755418T3 (en) 2020-04-22
AU2016355972A1 (en) 2018-07-05
CA3005492C (en) 2023-01-10
CN107920993A (en) 2018-04-17
DE112016003047T5 (en) 2018-03-29
KR102317281B1 (en) 2021-10-25
EP3639811B1 (en) 2024-03-20
AU2016355972A2 (en) 2018-07-19
EP3319587A1 (en) 2018-05-16
DK3319587T3 (en) 2019-11-25
CN112294758B (en) 2022-09-30
US20230116048A1 (en) 2023-04-13
CA3005492A1 (en) 2017-05-26
JP6710415B2 (en) 2020-06-17
EA201891115A1 (en) 2018-10-31
US20180243444A1 (en) 2018-08-30
DE202016008594U1 (en) 2018-08-23
WO2017085228A1 (en) 2017-05-26
CN112294757A (en) 2021-02-02
EP3319587B1 (en) 2019-08-21
HUE047172T2 (en) 2020-04-28
CN112294758A (en) 2021-02-02
CH713097B1 (en) 2019-07-15
PL3319587T3 (en) 2020-05-18
US10568971B2 (en) 2020-02-25
GB201801932D0 (en) 2018-03-21
IL257393A (en) 2018-06-28
DE112016003047B4 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
IL272238A (en) Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
HK1253018A1 (en) Taxane particles and their use
HK1251153A1 (en) Pharmaceutical composition and application thereof
IL252967A0 (en) Pharmaceutical composition comprising plasminogen and uses thereof
PL3448363T3 (en) Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
HK1245086A1 (en) Pharmaceutical composition preparation and uses thereof
ZA201703398B (en) Pharmaceutical composition and methods
HK1245085A1 (en) Pharmaceutical composition preparation and uses thereof
PL3145508T3 (en) Clevidipine nanoparticles and pharmaceutical compositions thereof
GB201406172D0 (en) Therapy and pharmaceutical composition
HK1214767A1 (en) Tablet-formed pharmaceutical composition and preparation method thereof
HK1245113A1 (en) Pharmaceutical compositions and use thereof
PT3503885T (en) Pharmaceutical composition and methods of uses
GB201519644D0 (en) Therapy and pharmaceutical composition
ZA201703078B (en) Pharmaceutical composition comprising bisoprolol and perindoril
IL250394A0 (en) Oral composition for delivery of drugs and other substances
EP3560492C0 (en) Lipid particle composition and pharmaceutical composition
AU2015901459A0 (en) Pharmaceutical powder composition and use